Type 2 poliovirus detection after global withdrawal of trivalent oral vaccine

BACKGROUND Mass campaigns with oral poliovirus vaccine (OPV) have brought the world close to the eradication of wild poliovirus. However, to complete eradication, OPV must itself be withdrawn to prevent outbreaks of vaccine‐derived poliovirus (VDPV). Synchronized global withdrawal of OPV began with serotype 2 OPV (OPV2) in April 2016, which presented the first test of the feasibility of eradicating all polioviruses. METHODS We analyzed global surveillance data on the detection of serotype 2 Sabin vaccine (Sabin‐2) poliovirus and serotype 2 vaccine–derived poliovirus (VDPV2, defined as vaccine strains that are at least 0.6% divergent from Sabin‐2 poliovirus in the viral protein 1 genomic region) in stool samples from 495,035 children with acute flaccid paralysis in 118 countries and in 8528 sewage samples from four countries at high risk for transmission; the samples were collected from January 1, 2013, through July 11, 2018. We used Bayesian spatiotemporal smoothing and logistic regression to identify and map risk factors for persistent detection of Sabin‐2 poliovirus and VDPV2. RESULTS The prevalence of Sabin‐2 poliovirus in stool samples declined from 3.9% (95% confidence interval [CI], 3.5 to 4.3) at the time of OPV2 withdrawal to 0.2% (95% CI, 0.1 to 2.7) at 2 months after withdrawal, and the detection rate in sewage samples declined from 71.0% (95% CI, 61.0 to 80.0) to 13.0% (95% CI, 8.0 to 20.0) during the same period. However, 12 months after OPV2 withdrawal, Sabin‐2 poliovirus continued to be detected in stool samples (<0.1%; 95% CI, <0.1 to 0.1) and sewage samples (8.0%; 95% CI, 5.0 to 13.0) because of the use of OPV2 in response to VDPV2 outbreaks. Nine outbreaks were reported after OPV2 withdrawal and were associated with low coverage of routine immunization (odds ratio, 1.64 [95% CI, 1.14 to 2.54] per 10% absolute decrease) and low levels of population immunity (odds ratio, 2.60 [95% CI, 1.35 to 5.59] per 10% absolute decrease) within affected countries. CONCLUSIONS High population immunity has facilitated the decline in the prevalence of Sabin‐2 poliovirus after OPV2 withdrawal and restricted the circulation of VDPV2 to areas known to be at high risk for transmission. The prevention of VDPV2 outbreaks in these known areas before the accumulation of substantial cohorts of children susceptible to type 2 poliovirus remains a high priority. (Funded by the Bill and Melinda Gates Foundation and the World Health Organization.)

[1]  Qi Chen,et al.  Vaccine-Derived Poliovirus Outbreaks and Events — Three Provinces, Democratic Republic of the Congo, 2017 , 2018, MMWR. Morbidity and mortality weekly report.

[2]  Hil M. Lyons,et al.  Evaluating cessation of the type 2 oral polio vaccine by modeling pre- and post-cessation detection rates. , 2017, Vaccine.

[3]  Michael Famulare,et al.  The risk of type 2 oral polio vaccine use in post-cessation outbreak response , 2017, BMC Medicine.

[4]  N. Grassly,et al.  Risk factors and short-term projections for serotype-1 poliomyelitis incidence in Pakistan: A spatiotemporal analysis , 2017, PLoS medicine.

[5]  O. Diop,et al.  Virologic Monitoring of Poliovirus Type 2 after Oral Poliovirus Vaccine Type 2 Withdrawal in April 2016 — Worldwide, 2016–2017 , 2017, MMWR. Morbidity and mortality weekly report.

[6]  R. Nielsen,et al.  The Evolutionary Pathway to Virulence of an RNA Virus , 2017, Cell.

[7]  Update on vaccine-derived polioviruses worldwide, January 2016–June 2017. , 2017, Releve epidemiologique hebdomadaire.

[8]  Population Immunity against Serotype-2 Poliomyelitis Leading up to the Global Withdrawal of the Oral Poliovirus Vaccine: Spatio-temporal Modelling of Surveillance Data , 2016, PLoS medicine.

[9]  L. Hampton,et al.  Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016. , 2016, MMWR. Morbidity and mortality weekly report.

[10]  N. Grassly,et al.  Preventing Vaccine-Derived Poliovirus Emergence during the Polio Endgame , 2016, PLoS pathogens.

[11]  S. Tegegne,et al.  Contribution of Environmental Surveillance Toward Interruption of Poliovirus Transmission in Nigeria, 2012–2015 , 2016, The Journal of infectious diseases.

[12]  Paul Chenoweth,et al.  Faster Detection of Poliomyelitis Outbreaks to Support Polio Eradication , 2016, Emerging infectious diseases.

[13]  F. Shuaib,et al.  Environmental isolation of circulating vaccine-derived poliovirus after interruption of wild poliovirus transmission, Nigeria, 2016. , 2016, Releve epidemiologique hebdomadaire.

[14]  Stewart T. Chang,et al.  Sabin Vaccine Reversion in the Field: a Comprehensive Analysis of Sabin-Like Poliovirus Isolates in Nigeria , 2015, Journal of Virology.

[15]  J. Meschke,et al.  Development of a novel bag-mediated filtration system for environmental recovery of poliovirus. , 2014, Journal of water and health.

[16]  K. Thompson,et al.  Modeling the dynamics of oral poliovirus vaccine cessation. , 2014, The Journal of infectious diseases.

[17]  S. Lowther,et al.  Environmental surveillance for polioviruses in the Global Polio Eradication Initiative. , 2014, The Journal of infectious diseases.

[18]  Roland W Sutter,et al.  The new polio eradication end game: rationale and supporting evidence. , 2014, The Journal of infectious diseases.

[19]  A. Levitt,et al.  Surveillance Systems to Track Progress Toward Global Polio Eradication — Worldwide, 2012–2013 , 2014, MMWR. Morbidity and mortality weekly report.

[20]  Meeting of the Strategic Advisory Group of Experts on Immunization, November 2012 – conclusions and recommendations. , 2013, Releve epidemiologique hebdomadaire.

[21]  N. Grassly,et al.  Waning intestinal immunity after vaccination with oral poliovirus vaccines in India. , 2012, The Journal of infectious diseases.

[22]  A. Tatem,et al.  Population Distribution, Settlement Patterns and Accessibility across Africa in 2010 , 2012, PloS one.

[23]  Update on vaccine-derived polioviruses--worldwide, July 2009-March 2011. , 2011, MMWR. Morbidity and mortality weekly report.

[24]  WatanabeSumio Asymptotic Equivalence of Bayes Cross Validation and Widely Applicable Information Criterion in Singular Learning Theory , 2010 .

[25]  N. Grassly,et al.  Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control study , 2007, The Lancet.

[26]  Frank Fenner,et al.  Public health. Is polio eradication realistic? , 2006, Science.

[27]  M. Pallansch,et al.  Vaccine-derived polioviruses and the endgame strategy for global polio eradication. , 2005, Annual review of microbiology.

[28]  M. Pallansch,et al.  Persistence of oral polio vaccine virus after its removal from the immunisation schedule in New Zealand , 2005, The Lancet.

[29]  M. Pallansch,et al.  Vaccine policy changes and epidemiology of poliomyelitis in the United States. , 2004, JAMA.

[30]  D. Heymann,et al.  Eradicating polio. , 2004, The New England journal of medicine.

[31]  Apparent global interruption of wild poliovirus type 2 transmission. , 2001, MMWR. Morbidity and mortality weekly report.

[32]  Francis Tuerlinckx,et al.  Diagnostic checks for discrete data regression models using posterior predictive simulations , 2000 .